Introduction
============

Growing awareness of the prevalence of environmental compounds, both synthetic and naturally occurring, with endocrine disrupting properties has generated considerable debate among scientists, regulatory agencies, and the general public about the potential long-term risks they pose for human and wildlife reproductive health. Is the endocrine disruption hypothesis plausible? Epidemiological evidence that human reproductive health is declining, particularly in Western nations, continues to mount. For example, sperm counts in Western countries appear to have declined by half in the past 50 years (Carlsen et al., [@B35]; Swan et al., [@B206]). In Demark, it is now estimated that more than 10% of men have sperm counts in the infertile range and up to 30% are in the subfertile range (Joensen et al., [@B106]). There are also indications that female fecundity is declining, even among young women, although the rate and degree to which this is occurring has been difficult to quantify (Brannian and Hansen, [@B25]; Frey and Patel, [@B67]; Nyboe Andersen and Erb, [@B145]). Within the United States, median age at menarche, first breast development, and sexual precocity has steadily advanced, especially among minority populations (Herman-Giddens et al., [@B92]; Partsch and Sippell, [@B152]). Similar trends have been noted in Europe and among children adopted from developing countries by Western parents (Aksglaede et al., [@B7]; Parent et al., [@B151]; Proos et al., [@B165]). The cause is likely complex and multi-faceted, but rapidity of the increase in reproductive and behavioral disorders suggests an environmental component. Whether or not endocrine disrupting compounds (EDCs) could be a contributing factor remains the subject of intense scrutiny and other determinants such as diet, stress, and body weight likely also play a role. At issue are both the degree to which low dose exposures to compounds with low hormonal potency can produce appreciable effects in the vertebrate reproductive system, and the difficulty of adequately assessing the potential long term risks of compounds with sex-, life stage-, and tissue-specific effects. Both issues are difficult to address experimentally because the timing, duration and level of human exposure are often uncertain. Moreover, the latency between EDC exposure and the emergence of consequential health effects can be considerably long, even decades, and the degree to which gene-environment interactions can produce inter-individual variability is poorly understood. Finally, predicting human responses from sentinel wildlife cases and from *in vitro* and animal tests of endocrine action is not straightforward. Nonetheless, there is reasonable and increasing evidence from *in vitro* and animal studies to suggest cause for concern. This review will address the potential long term physiological and behavioral effects of exposure to environmental endocrine disruptors in vertebrates, the evidence for human risk, and how this issue has transformed both endocrinology and toxicology.

An EDC is defined (in part) by the United States Environmental Protection Agency (EPA) as, "an exogenous chemical substance or mixture that alters the structure or function(s) of the endocrine system and causes adverse effects....at the level of the organism, its progeny, and populations or subpopulations of organisms." This definition includes disruption of lactation, sexual maturation, the ability to produce viable, fertile offspring, sex specific behavior, and premature reproductive senescence. To date, the EPA has identified hundreds of compounds that fit this definition and thousands of others are suspected of having similar properties[1](#fn1){ref-type="fn"} (Crisp et al., [@B46]; Toppari et al., [@B214]). Some of these compounds, such as oral contraceptives and a subset of pesticides, were specifically developed to target the endocrine system but the vast majority of chemicals on the EPA\'s list were neither designed nor intended to, especially in mammals. Some, such as DDT or the pyrethrins were developed to kill mosquitoes and other pests that spread serious and in some cases life threatening human diseases such as malaria. Others were devised as flame retardants, to kill weeds, or to make plastics harder, clearer, and more resistant to heat stress (bisphenol-a) or more pliable (the phthalates). Compounds produced in nature rather than by humans, such as the phytoestrogens, also fit this definition (Figure [1](#F1){ref-type="fig"}).

![**Chemical structures and uses of common endocrine disruptors**. DES, bisphenol-a and genistein are classified as estrogen agonists while both of the phthalates are androgen antagonists. DDT is classified as both an estrogen agonist and an androgen antagonist.](fnbeh-03-010-g001){#F1}

DDT: The First Known Endocrine Disruptor
========================================

The discovery that chemicals could interfere with the endocrine system in non-target species was first made by wildlife biologists who noted rapid population declines and abnormal reproductive physiology and behavior in multiple species. For example, as early as the 1930s, famed Florida naturalist Charles Broley noticed abnormal courtship behavior, reduced nesting behavior, and diminishing birth rates among numerous bird species all across the United States and Canada, most notably bald eagles. His behavioral observations ultimately led him to hypothesize that heavy consumption of fish tainted with the widely used pesticide dichlorodiphenyltrichloroethane (DDT) was sterilizing the birds (Beans, [@B17]). This contention launched an unprecedented investigation by scientists who both doubted and embraced his hypothesis. It was ultimately determined that DDT and its metabolites, although they did not cause sterility (sperm counts in the birds were normal), feminized male embryos, weakened eggshells, and interfered with reproductive behavior to such a significant degree that it was decimating bird populations. These and similar cases were eloquently documented in the instant best selling book *Silent Spring* by Rachel Carsen (1962), the publication of which launched the modern environmental movement. She postulated that by liberally spraying pesticides in our zealous determination to destroy "pests," we were risking the systemic destruction of ourselves and our environment. This thesis fundamentally changed the public\'s perception of pesticide use and a decade later, DDT was ultimately banned in the United States largely as a result of public pressure.

The dramatic DDT story demonstrated that exposure to a compound not designed to interact with the endocrine system could induce profound reproductive deficits in non-target species. Despite this however, the capacity for DDT and its metabolites to impact human health is still widely disputed, particularly when exposure occurs at "low levels" rather than through an industrial accident or other large scale mechanisms. At high doses DDT is a potent neurotoxin, but numerous studies in laboratory animals, and *in vitro* assays have established that at low doses it can act as an endocrine disruptor. Even though DDT is no longer used in the US, human exposure to DDT and its metabolites is ongoing. For example, the primary metabolite of DDT, DDE, is far more persistent than the parent compound and thus still found in the environment at low levels. It is also highly lipophilic and accumulates in fat, so body burden increases with age. In addition, DDT is still used in many parts of the world, especially where the risk of contracting malaria, a disease which kills more people than cancer, heart disease or the HIV virus, is great. According the World Health Organization (WHO) nearly a million people died of malaria in 2006, 91% of them children[2](#fn2){ref-type="fn"}. In contrast, no one is known to have died from routine DDT use. Whether or not DDT can induce disease or impair reproductive development in humans remains the subject of investigation and a controversial topic. A recent epidemiology study associated *in utero* or neonatal exposure with an increased risk of breast cancer (Cohn et al., [@B41]) a study which adds to a body of literature suggesting that prepubertal exposure to DDT may increase the risk of breast cancer (Clapp et al., [@B37]). Unfortunately many of the epidemiological studies exploring a potential association between DDT exposure and breast cancer risk have methodological weakness which make the data difficult to interpret, and many scientists remain skeptical that DDT exposure is a causative factor for breast cancer development (Beard, [@B18]). Emerging evidence from areas where DDT is still used suggests that DDT exposure might also be associated with other diseases including preterm birth, early pregnancy loss, reduced semen quality, disrupted menstruation, and problems with lactation (Beard, [@B18]; Rogan and Chen, [@B171]; Venners et al., [@B219]). But other factors, such as unreliable access to clean water and adequate nutrition are potential confounds and birth rates in these areas remain high. Nursing infants from these regions are frequently exposed to levels in breast milk which exceed the acceptable daily intake of 20 μg/kg body weight per day established by the WHO. Therefore the potential reproductive risk of DDT exposure is ongoing for many populations outside the US.

DDT, its metabolites, and the majority of other endocrine disruptors are now known to affect the endocrine system by multiple mechanisms, most notably by acting as weak estrogen agonists. Thus, the hypothesis that endocrine disruption is a significant health concern for humans would be strengthened by the demonstration that exposure to synthetic estrogens, particularly early in development, can have lasting effects. Unfortunately, this link has already been made.

Evidence of the Potential for Estrogenic Endocrine Disruptors to Affect Human Health
====================================================================================

The clearest evidence that exposure to estrogen during fetal development can impact human reproductive health emerged from the widespread use of the potent synthetic estrogen diethylstilbestrol (DES, Figure [1](#F1){ref-type="fig"}). Beginning in 1938, DES was initially prescribed to prevent miscarriage but ultimately advertised and dispensed to pregnant women in general to produce "stronger babies" and even administered to newborns to enhance weight gain (Karnaky, [@B108]; Kuchera, [@B114]; Palmlund, [@B148]; Smith, [@B197]). It is estimated that DES was taken by four to six million (and possibly as many as 10 million) pregnant women in the US alone before human use was suspended in 1971 (Giusti et al., [@B71]). Non-medical use of DES was also common and thus a significant source of DES exposure, albeit in lower does. For example, it was frequently used in cosmetics, lotions, shampoo, and as a growth promoter in chicken and cattle. DES implants in poultry were outlawed in 1959 when DES residues were found in chicken liver, however this did not affect the use of DES in cattle, which remained ubiquitous until it was ultimately phased out in 1979. By the 1980s, more than 80% of US cattle were estimated to have been exposed, and considerable release of DES into the environment through feed lots and cattle waste has been well documented (Metzler, [@B134]; Zervos and Rodricks, [@B241]).

Unfortunately DES was ineffective at preventing miscarriage (Dodds et al., [@B52]) but the reproductive consequences to the developing offspring (both male and female) would ultimately prove to be extensive. One consequence of *in utero* DES exposure was first identified in 1971 by a group of keen eyed physicians who noticed that girls born to mothers who took DES during pregnancy (collectively referred to as "DES daughters") were more likely to develop an extremely rare type of cervicovaginal clear-cell adenocarcinoma (CCAC) (Herbst et al., [@B90], [@B91]). One in 1000 DES daughters is now estimated to have developed CACC by the age of 34 (Giusti et al., [@B71]; Rubin, [@B173]) which is an extraordinarily high rate for such a rare form of cancer. DES exposure is also associated with increased incidences of vaginal dysplasia, vaginal and cervical adenosis and abnormalities of the cervix, vagina, and uterus. DES daughters suffer from reduced fertility, a higher risk of infertility, and more complicated and unsuccessful pregnancies. Complications include ectopic pregnancy, late spontaneous abortions and premature delivery (Palmlund, [@B148]; Palmlund et al., [@B149]). Increased rates of psychiatric disorders including depression, anorexia, phobias and learning disabilities have also been reported (Vessey et al., [@B220]). Damage from DES exposure is not limited to females. DES sons are also affected and show elevated rates of urogenital malformations, undescended testes, and testicular cancer. Low sperm density and mobility has also been observed (Gill et al., [@B70]; Palmer et al., [@B147]; Stenchever et al., [@B200]; Wilcox et al., [@B232]).

Most of the reproductive outcomes following fetal exposure to DES were predicted by or replicated in animal models (McLachlan et al., [@B132]; Newbold, [@B141]; Newbold and McLachlan, [@B144]). Thus, this unfortunate event in human medical history illustrates both the vulnerability of the developing fetus to estrogenic endocrine disruptors and the importance of animal models for predicting potential adverse effects in humans. Similarly, experimental work in multiple species was equally critical for establishing a causal link between DDT exposure and abnormal reproductive behavior accompanied by compromised fertility in wildlife populations (Beans, [@B17]; Guillette and Gunderson, [@B83]; Toppari et al., [@B214]). Therefore the importance of animal models in human risk assessment paradigms should not be underappreciated.

Key Concepts of Endocrine Disruption: Timing, Dose and Nonlinear Effects
========================================================================

The impact of the DES tragedy on the field of toxicology was transformative and three key principles of endocrine disruption emerged. First, the latency between fetal insult and the manifestation of physical or behavioral dysfunction can be extremely long, even decades. This concept had long been recognized by behavioral endocrinologists including Beach, Young, Goy and others exploring the mechanisms by which fetal hormone exposure could alter sexual behavior and sex specific neuroendocrine feedback systems (Balthazart et al., [@B13]; Gorski, [@B73]; Goy and Resko, [@B78]; Marler, [@B129]; Swaab and Hofman, [@B204]; Young et al., [@B240]), but was a breakthrough for toxicologists. It is now the basis for a conceptual framework termed the "fetal basis of adult disease," an idea that has transcended the endocrine disruption field. The concept that exposure to environmental factors, including toxicants, during fetal or neonatal life can interact with the genome and influence diseases which emerge years later including cancer, infertility, precocious puberty and obesity is potentially revolutionary and is currently a "hot topic" of research.

A second key concept of endocrine disruption is that the dose response of many hormones and EDCs appears to be nonmonotonic. This paradigm is anathema to the fundamental toxicological principle that "the dose makes the poison." The standard approach in toxicology, for experiments looking at acute exposure, is to expose either cells or animals to a few, generally high, concentrations of a given chemical. Selection of those doses is traditionally based on one of two standardized measurements called the LD~50~, which is the dosage lethal to 50% of the exposed organism or cells, and the lowest observed effect concentration (LOEC), which is the lowest concentration that produces readily observable morphological deformities. Similar designs using high (often near-lethal) doses that are not considered environmentally relevant are frequently used for subchronic and chronic exposure studies as well. These approaches assume that adverse effects increase proportionally and predictably with exposure level (generally linear or sigmoidal) and there is a threshold below which no effect is observed (termed the no observable adverse effect level or NOAEL). A level 1000-fold lower is then deemed the "safe" or "reference dose" for humans. With this model, potential low dose effects can be extrapolated from studies where doses in the range of the LD~50~ (or LOEC) are used. It also assumes that the observed effects will be obvious and include readily appreciable abnormalities. Unfortunately, there is growing evidence to suggest that the effects produced by hormones and many endocrine disruptors are not adequately predicted by this model because they have nonmonotonic dose responses that more closely approximate a U-shaped or inverted U-shaped curve (Andersen et al., [@B8]; Hayes et al., [@B87]; Sheehan, [@B188]; Vandenberg et al., [@B218]). In addition, effects, as seen with DES and CCAC, are likely to be more insidious and thus potentially difficult to readily identify. It is unclear how compounds can produce U-shaped dose effects but this response likely reflects an integration of two different mechanisms of action, each of which occurs at a different dose range (Vandenberg et al., [@B217]). Thus a compound like DDT could potentially interfere with estrogen (or androgen) action at low doses but act as a potent neurotoxin at levels closer to the LD~50~ (Toppari et al., [@B214]). It should be noted that although some toxicologists have expressed concern that nonmonotonic dose responses are underappreciated (Calabrese, [@B28]; Calabrese and Baldwin, [@B29]), others doubt their existence (Crump, [@B47]) and the concept remains highly contentious (Lutz et al., [@B123]; Melnick et al., [@B133]; Vandenberg et al., [@B217]).

A final principle of endocrine disruption made evident by the DES story is that the timing of exposure is crucial. The presence and extent of disorders common to DES sons and daughters varies substantially depending on the timing of the mother\'s first exposure, total dose, and length of exposure (Faber et al., [@B60]; Robboy et al., [@B169], [@B170]). In humans and animals, there are critical windows of development, both for the reproductive organs and the brain, when sensitivity to hormones and EDCs is heightened. Again, this was not a novel concept to neuroendocrinologists but was previously underappreciated by toxicologists. Within this concept is also the recognition that the placenta is not impenetrable to EDCs and that, on the contrary, most EDCs likely reach the developing fetus. Maternal estrogens are effectively sequestered by α-fetoprotein but most estrogen-like compounds only weakly or fail to bind to α-fetoprotein and can therefore enter fetal circulation relatively unimpeded (Ikezuki et al., [@B98]; Milligan et al., [@B135]; Vandenberg et al., [@B216]). It is now widely accepted that development is a window of exceptional vulnerability to EDC exposure.

Organization of Reproductive Neuroendocrine Circuits
====================================================

During early development (gestation in humans, gestation and early neonatal life in rodents), the neuroendocrine feedback loops which regulate sex-specific reproductive physiology and behavior are sexually differentiated and organized. The coordination of physiological events and appropriate behavioral responses to them is paramount to reproductive fitness and the stability of a population. For example, the reproductive fitness of an ovulating female that fails to mate or nurse her young is just as diminished as the reproductive fitness of a female that fails to ovulate. Similarly, a male who responds to a soliciting female with aggression rather than courtship has a significantly decreased chance of passing along his genome even if he is physiologically capable of doing so. Thus, populations can be at risk when the integration of behavioral responses to physiological and environmental cues is disrupted. The organization of the neuroendocrine circuits that coordinate sex-specific physiology and behavior is orchestrated largely by steroid hormones, particularly estrogen, during distinct critical periods in embryonic and postnatal development (Cooke et al., [@B42]; Gorski, [@B74]; Simerly, [@B190], [@B191]). The organization of these circuits appears to be particularly vulnerable to disruption by EDCs.

Maturation and function of the vertebrate reproductive system is coordinated by the hypothalamic-pituitary-gonadal (HPG) axis. This system encompasses a complex network of neuronal signaling pathways that enable the regulation of gonadotropin secretion by steroid hormones (Elkind-Hirsch et al., [@B59]; Gorski et al., [@B75]). The neural components of the HPG axis span multiple brain areas, primarily the hypothalamus, a diencephalic region important for coordination of many neuroendocrine functions including hunger, thirst, circadian cycles, emotion, body temperature and stress in addition to reproduction. It is responsive to a litany of external signals including day length, hormones, olfactory cues, and glucose levels, among others. Contained within the hypothalamus are discrete populations of neurons that regulate gonadotropin releasing hormone (GnRH) secretion. The network of regulatory inputs from neuronal and glial cells in the brain projecting to these neurons is sexually differentiated by endogenous gonadal hormones (primarily estradiol in rodents but perhaps both estrogens and androgens in humans) through a series of gestational, pre- and perinatal critical periods (Cooke et al., [@B42]; Gorski, [@B74]; Simerly, [@B190], [@B191]). In the post-pubertal animal, GnRH release is regulated through feedback effects of gonadal steroids. In both males and females, GnRH secretion is suppressed by steroid negative feedback, the signal for which is thought to arise from the arcuate nucleus (ARC) of the hypothalamus (Kauffman et al., [@B110]; Tena-Sempere, [@B209]). In females, however, GnRH release is augmented once per cycle by estrogens. This positive feedback potentiates the surge in GnRH and, subsequently, luteinizing hormone (LH) that precedes ovulation (Clarke and Pompolo, [@B38]). This process is now thought to be mediated within the anterior hypothalamus (Adachi et al., [@B1]; Kauffman et al., [@B110]; Tena-Sempere, [@B209]) and the sex specific organization of this system can be manipulated, inducing long term consequences. For example, it is well established that the administration of steroid hormones, including androgens or estrogens, during the neonatal critical period can masculinize the female rodent brain while castration can effectively prevent defeminization of the male rodent brain (Bakker and Baum, [@B12]; Baum, [@B16]; Simerly, [@B191]). Thus, in males castrated as neonates, the potential for estrogen to evoke a GnRH surge is preserved while, conversely, in females neonatally exposed to estrogens, this capacity is diminished or lost.

The neuroendocrine pathways regulating reproductive behavior are similarly organized and affected by steroid hormones. In rats, lordosis is a reflexive receptive posture made by the female in response to male mounting and is a hallmark indication of sexual receptivity. Whereas circulating estrogens play an essential role in stimulating lordosis in females (Davidson and Bloch, [@B49]; Lisk, [@B122]; Komisaruk and Diakow, [@B111]; Pfaff, [@B160]; Pfaff and Sakuma, [@B161]), males rarely display lordosis behavior even after estrogen administration in adulthood (Yamanouchi and Aria, [@B238]). However, neonatal steroid hormone manipulation can retain in the capacity to evoke lordosis in males, and suppress proceptive behavioral displays by females, indicating that sex-specific behaviors are also organized by steroid hormones in the perinatal period (Gerall, [@B69]; Gorski, [@B73], [@B74]; Grady et al., [@B79]; Sodersten, [@B198]; Patisaul et al., [@B154]; Whalen and Nadler, [@B230]; Whales et al., [@B231]). Thus, aberrant organization of sex specific neuroendocrine circuits can have profound and permanent effects on sex specific reproductive physiology and behavior. Consequently, the organization of neuroendocrine pathways is considered to be particularly vulnerable to endocrine disruption. Most examples detailed within this review result from endocrine disruption of the neuroendocrine system.

Low Dose Effects: Health Risk or Hype?
======================================

It is now evident that exposure to endocrine disruptors has the potential to adversely affect reproductive physiology and behavior in vertebrates. The critical question now is if wildlife and human health is at risk from chronic exposure to low doses of these compounds, either alone or in mixtures. DDT was applied liberally and has a long half life, thus affected wildlife populations had relatively high exposure levels. Moreover, DES has a binding affinity for ERα and ERβ that is roughly equivalent to estradiol and is therefore a potent estrogen agonist (Korach et al., [@B112]; Sadler et al., [@B175]). Most endocrine disruptors exist at far lower levels in the environment and have binding affinities 100--10,000 times lower than either estradiol or DES. In some cases, however, blood levels of these compounds can be several fold higher than endogenous estrogen levels and suspected endocrine disruptors are almost always present in both the environment and in bodily fluids as mixtures. Although DDT and many other EDCs are classified as "weak estrogens" the precise mechanisms through which they interact with the vertebrate neuroendocrine system and the exposure levels that produce substantive effects are still largely undetermined. For example, DDT (and its metabolites) is now appreciated to act as both an estrogen agonist and an androgen antagonist highlighting the potential for compounds to have multiple mechanisms of action. Direct binding to steroid receptors is only one mode of action. Endocrine disruption also includes interference with the biosynthesis, transport, or metabolism of hormones or the disruption of the recruitment of binding proteins or transcription factors. Another key issue that remains poorly understood is how these compounds behave within mixtures. Wildlife and human populations are exposed to dozens if not hundreds of compounds simultaneously yet very little is known about how these compounds interact either *in vitro* or *in vivo*.

For simplicity, to address the question of whether or not endocrine disruptors have the potential to affect reproductive physiology and behavior at low doses, this review will focus on three compounds currently gaining wide scientific and public attention: genistein, bisphenol-a (BPA) and the phthalates. genistein and BPA are classified as weak estrogen agonists and thus presumably have similar mechanisms of action (Figure [1](#F1){ref-type="fig"}). However, genistein, because it is produced by plants and found in soy foods, is widely perceived as healthful while BPA, a component of polycarbonate plastics and epoxy resins, is commercially produced and was recently classified as a toxin in Canada (April, 2008). These attitudes are incongruous if the two compounds indeed elicit similar effects and therefore warrant further comparative investigation. The phthalates are found in a wide variety of products including cosmetics, pharmaceuticals, toys and medical devices. They are classified as androgen antagonists and their use was recently restricted in the US.

Genistein and Female Reproductive Physiology
============================================

The endocrine disrupting potential of phytoestrogens was first noticed in Australia in the 1940s when abnormally high rates of infertility, abortion, and reproductive abnormalities in newborn lambs were observed in ewes grazing on clover rich pastures (Bennetts and Underwood, [@B19]; Bennetts et al., [@B20]). It was ultimately determined that the steroid-like flavonoid phytoestrogens, most notably coumestrol, were responsible for the observed effects (Adams, [@B3],[@B4]; Braden et al., [@B24]). Decades later, a singular case of infertility and liver disease in captive cheetahs placed on a soy-based diet was ultimately attributed to the same class of compounds (Setchell et al., [@B183]). These incidents are reminiscent of the DDT story in wild bird populations, and have raised questions regarding the potential risk flavonoid phytoestrogens might pose to humans.

The two major classes of phytoestrogens are the lignans and the isoflavonoids. Lignans are minor components of cell walls and the highest concentrations are found in flaxseed (linseed) products, pumpkin seeds, green tea, coffee, and other fiber-rich foods (Axelson et al., [@B11]; Kuhnle et al., [@B116]; Mazur and Adlercreutz, [@B131]; Penalvo et al., [@B159]; Thompson et al., [@B212], [@B211]). The isoflavonoids are most prevalent in legumes, especially soybeans and soy-based foods including soy infant formula, tofu and soy milk, but detectable levels also occur in fruits, vegetables, whole grains, and even some alcoholic beverages (Adlercreutz and Mazur, [@B6]; Fletcher, [@B61]; Franke et al., [@B63]; Lapcik et al., [@B119]; Reinli and Block, [@B167]; Setchell et al., [@B184]). Dietary supplements containing high levels of isoflavonoid phytoestrogens are now widely available (Setchell et al., [@B182]). Of the many isoflavonoids found in soy, the most intensely scrutinized are genistein and daidzein.

Considerable attention is now being paid to the potential endocrine disrupting properties of isoflavonoids because soy consumption is widely promoted as being healthful and has been associated with reduced risk of cardiovascular disease and hormone dependent cancers (Adlercreutz and Mazur, [@B6]; Clarkson, [@B40]; Demonty et al., [@B51]; Peeters et al., [@B158]). In 1999, the US Food and Drug Administration (FDA) approved the health claim that daily consumption of 25 g of soy protein can reduce the risk of coronary artery disease (Food and Drug Administration, [@B62]). Soy consumption is increasing among all age groups, especially infants and children (Cao et al., [@B34]; Setchell, [@B181]; Strom et al., [@B201]). Genistein and other phytoestrogens readily cross the placenta indicating that fetal exposure is also potentially consequential (Todaka et al., [@B213]). Total isoflavone content in soy infant formula varies but is consistently high among soy foods, averaging near 40 μg total isoflavones per gram of formula (Franke et al., [@B64]; Johns et al., [@B107]; Setchell and Welsh, [@B185]; Setchell et al., [@B186]). This translates to a daily intake of approximately 6--9 mg/kg body weight per day, an amount, when adjusted for body weight, which is four to seven times higher than the amount consumed by adults on a traditional soy-based Asian diet or meeting the FDA guidelines (Barnes, [@B14]) and considerably higher than any synthetic EDC.

So is there cause for concern? The sheep and cheetah cases are disquietingly similar to the bird and other wildlife studies of the 1970s which ultimately identified the endocrine disrupting properties of DDT. But even today the question of whether or not DDT can impact human health is controversial, and such is the case with soy phytoestrogens. Is there any reasonably good evidence that phytoestrogens can have long term adverse health effects in humans following developmental exposure? A pair of studies on Puerto Rican girls associated neonatal phytoestrogen exposure with advanced pubertal onset, but a number of confounding factors including the use of potent estrogens in meat production, make the data problematic and difficult to interpret (Freni-Titulaer et al., [@B66]; Schoental, [@B178]). A more recent, retrospective cohort study found that young women fed soy-based infant formula as part of a controlled, University of Iowa feeding study reported longer menstrual bleeding and menstrual discomfort than those who were fed a non-soy based formula as babies (Strom et al., [@B201]). Beyond these epidemiology studies, very little is known about how exposure to soy phytoestrogens, either in the womb or in infancy, impacts female reproductive health or behavior in humans.

Data from animal research is more abundant. Neonatal exposure to genistein advances pubertal onset, increases the length of the estrous (menstrual) cycle and hastens the onset of persistent estrus in rodents. Female mice treated with 0.5--50 mg/kg genistein for only the first 5 days of life give birth to fewer live pups over time compared to untreated control animals, with fertility most strongly impacted at the highest dose (Jefferson et al., [@B102]). This acceleration of reproductive senescence could result from disruption anywhere within the HPG axis including the ovary and brain. Detailed work in mice by Jefferson and colleagues has revealed that genistein can interfere with ovarian differentiation resulting in ovarian malformations indicative of impaired fecundity such as multi-oocyte follicles, and attenuated oocyte cell death (Jefferson et al., [@B101], [@B103], [@B104]). Ovarian defects, including the absence of corpora lutea, the presence of large antral-like follicles with degenerating or no oocytes and numerous ovarian cysts have also been observed following neonatal genistein exposure in rats (Kouki et al., [@B113]) (Figure [2](#F2){ref-type="fig"}).

![**Frequently observed ovarian malformations in rats following neonatal exposure to endocrine disruptors**. **(A)** An ovary from an unexposed adult female contains follicles at all stages of folliculogenesis and numerous corpora lutea (CLs), indicative of successful ovulation. **(B)** Ovaries from females neonatally treated with the synthetic estrogen estradiol benzoate (25 μg) show no signs of folliculogenesis, are undersized and lack CLs. The presence of numerous, large antral-like follicles (AF) most of which contain a degenerating or no oocyte and are frequently reminiscent of ovarian cysts, are commonly observed following neonatal exposure to **(C)** BPA (50 mg/kg bw) or **(D)** genistein (10 mg/kg bw). CLs are often absent or significantly reduced in number when numerous AFs are present. A multi-oocyte follicle **(E)** in a pre-pubertal ovary following neonatal treatment with estradiol benzoate (10 μg).](fnbeh-03-010-g002){#F2}

Recent studies in our laboratory have found that the organization of sexually differentiated neural pathways within the hypothalamus is also vulnerable to neonatal endocrine disruption by genistein. We determined that advanced vaginal opening and abnormal estrous cyclicity, induced by neonatal exposure to 10 mg/kg genistein, is accompanied by an impaired ability to stimulate GnRH neuronal activity (as measured by the immunoreactivity of both of GnRH and Fos) following ovariectomy and hormone priming (Bateman and Patisaul, [@B15]) (Figure [3](#F3){ref-type="fig"}). This observation indicates that neonatal genistein exposure has a masculinizing effect on the female HPG axis. Although GnRH neurons express ERβ throughout development (Herbison and Pape, [@B89]; Hrabovszky et al., [@B96], [@B97]) and thus could potentially respond to neonatal genistein directly, it is generally accepted that hormonal and other environmental signals are largely conveyed to GnRH neurons from other estrogen-responsive neurons clustered in different regions of the hypothalamus. In rodents, the two most significant regions appear to be the anterior ventral periventricular (AVPV) and arcuate (ARC) nuclei (Gu and Simerly, [@B81]; Polston et al., [@B163]; Polston and Simerly, [@B164]; Shughrue et al., [@B189]; Simerly et al., [@B192]) both of which contain sexually dimorphic populations of neurons that express the KiSS-1 gene. This gene codes for a family of peptides called kisspeptins (previously called metastins), and rapidly emerging evidence indicates that kisspeptin neurons are essential for coordinating pubertal onset and steroid feedback on GnRH neurons in many species, including humans (Kauffman et al., [@B109]; Navarro et al., [@B139]; Smith et al., [@B195],[@B196]). AVPV kisspeptin neurons are more numerous in females than males and are thought to be essential for steroid positive feedback and the initiation of the preovulatory GnRH surge (Clarkson et al., [@B39]; Gottsch et al., [@B76]; Irwig et al., [@B100]; Kauffman et al., [@B109], Roa et al., [@B168]; Smith et al., [@B196]). In contrast, KiSS mRNA expression in the ARC is not thought to be sexually dimorphic and appears to be important for the regulation of steroid negative feedback (Kauffman et al., [@B109]). We have now shown that neonatal exposure to 10 mg/kg genistein can significantly decrease the density of neuronal fibers immunolabeled for kisspeptin in the AVPV but not the ARC of female rats (Bateman and Patisaul, [@B15]; Patisaul et al., [@B157]) indicating that disrupted organization of the kisspeptin signaling pathways may be a novel yet fundamental mechanism by which a suite of reproductive abnormalities are induced including disrupted timing of pubertal onset, irregular estrous cycles and premature anovulation.

![**Effects of neonatal exposure to genistein (GEN, 10 mg/kg bw) compared to an oil based vehicle (OIL), and estradiol benzoate (EB, 50 μg) on reproductive physiology and behavior in female rats**. **(A)** GEN significantly advanced the timing of pubertal onset as measured by day of vaginal opening compared to control females. **(B)** This corresponded with anovulation (by 15 weeks of age) in 43% of GEN females, compared to none of the OIL females and all of the EB females. **(C)** There was no effect of GEN on sexual receptivity (following ovariectomy and hormone priming) however **(D)** the number of GnRH neurons also immunopositive for Fos was significantly reduced indicating an impaired capacity to display steroid positive feedback. (Panels **(A)** and **(D)** adapted from Bateman and Patisaul, [@B15]).](fnbeh-03-010-g003){#F3}

Interestingly, animals exposed to genistein neonatally remained capable of displaying lordosis when ovariectomized, primed by the sequential administration of estradiol benzoate and progesterone, and paired with vigorous males (Figure [3](#F3){ref-type="fig"}). Lordosis behavior is also retained by female rats neonatally exposed to agonists selective for either ERα or ERβ but not estradiol benzoate suggesting that agonism of both ER subtypes may be needed to fully defeminize the behavior (Patchev et al., [@B153]; Patisaul et al., [@B154]). It may also take a longer exposure or higher doses, a possibility which illustrates the important concepts of dose and timing when considering the potential effects of EDCs. Further complicating the issue is a report that selective agonism of ERβ results in a statistically significant reduction, but not elimination, of lordosis behavior in mice (Kudwa et al., [@B115]). This could be a species difference in sensitivity or the relative role ERβ plays in the organization of the neuroendocrine pathways that mediate the lordosis response. Further work will be needed to clarify this issue.

The mechanisms by which genistein and the other phytoestrogens influence sex-specific physiology are likely diverse. Genistein has a higher relative binding affinity for both ERα and ERβ *in vitro* than most other EDCs and a higher binding affinity for ERβ that for ERα (Kuiper et al., [@B117]). Genistein is also a potent inhibitor of tyrosine protein kinases (Boutin, [@B23]; Piontek et al., [@B162]), which catalyze phosphorylation of their own tyrosine residues and those of other proteins, including growth factors involved in tumor cell proliferation. In addition, genistein can also inhibit DNA topoisomerases I and II, enzymes essential for DNA replication (Kurzer and Xu, [@B118]; Okura et al., [@B146]) and may also work through epigenetic mechanisms involving both hyper and hypomethylation (Dolinoy et al., [@B55]; Tang et al., [@B208]). A further complication is the observation that effects of genistein administration at low doses are compounded when co-administered with other EDCs (Kurzer and Xu, [@B118]; You et al., [@B239]). Mixture effects of phytoestrogens, as with most other EDCs, are generally unappreciated.

Bisphenol-A (BPA): A Dynamic and ongoing Controversy
====================================================

BPA is somewhat unique among EDCs because, in the early twentieth century, it was being developed as a possible synthetic estrogen (a pursuit which was abandoned following the synthesis of DES) (Dodds and Lawson, [@B53]). Since the 1950s, it has been used primarily in the production of polycarbonate plastic products to improve clarity and increase resilience. It is also a component of epoxy resins used to line the interior of metal cans such as soda and soup cans. Human exposure to BPA occurs through everyday use of these items because it can migrate from the container into the contents, especially when heated (Brede et al., [@B26]). The United States Centers for Disease Control recently estimated that nearly all Americans have detectable levels of BPA in their bodies, with children having higher levels than adults (Calafat et al., [@B30], [@B33]). Infants in neonatal intensive care units have particularly high exposure to BPA, presumably from its use in medical devices and from the migration of BPA into infant formula from the container (Calafat et al., [@B32]). In addition, newborns can be exposed through lactational transfer (Tsutsumi, [@B215]) and relatively high levels in umbilical cord blood and fetal serum (compared to maternal blood levels) indicate that BPA fails to bind α-fetoprotein and can expose the developing fetus (Ikezuki et al., [@B98]; Vandenberg et al., [@B216]). Exposure to BPA is not limited to humans, and effects on wildlife from contaminated water supplies have been documented in both males and females of multiple species (Crain et al., [@B43]; Maffini et al., [@B125]; vom Saal et al., [@B222]).

Although it was once thought that BPA could function as a synthetic estrogen, BPA was not considered to pose a significant threat to either wildlife or human populations because its binding affinity for the primary forms of the estrogen receptor (ERα and ERβ) is approximately 10,000-fold weaker than that of estradiol or DES (Gould et al., [@B77]; Kuiper et al., [@B117]). Yet, numerous studies from multiple laboratories have shown that BPA can impact reproductive physiology and behavior in rodents at doses even lower than the current reference or "safe" exposure limit for humans of 50 μg/kg body weight per day (Vandenberg et al., [@B217]). The mechanism(s) of low dose activity remains poorly understood but has long been hypothesized to be most potent in hormone sensitive organs and brain regions when endogenous estrogens are low or absent (vom Saal and Moyer, [@B223]). Thus, like DES, at different life stages BPA may have profoundly different effects on the same brain region or organ. It may also act through nonclassical estrogen pathways such as those mediated via membrane ERs, GPR30 or the newly discovered estrogen-related receptor --γ (ERR-γ) (Matsushima et al., [@B130]; Thomas and Dong, [@B210]; Watson et al., [@B228]).

Despite the controversy surrounding the mechanism by which low dose exposure to BPA could affect reproductive physiology, the evidence for widespread effects in animal models is increasing. Effects of perinatal exposure observed at the 50 μg/kg body weight dose or lower include advanced vaginal opening and the hastened onset of first estrus indicating advanced puberty (Adewale et al., (in press); Honma et al., [@B95]). Ovarian malformations including increased number of blood-filled ovarian bursae, indicative of advanced reproductive aging, abnormal numbers of antral follicles, aneuploidy and decreased corpora lutea (Figure [2](#F2){ref-type="fig"}) have also been observed by us and others (Adewale et al., (in press); Markey et al., [@B126]; Susiarjo et al., [@B203]). BPA can also induce apoptosis and cell arrest in cultured ovarian granulosa cells (Xu et al., [@B237]). Prolonged, irregular estrus cycles are also frequently observed by us and others following perinatal exposure to low doses suggesting compromised fertility (Adewale et al., (in press); Markey et al., [@B126]). Mammary gland development appears to be particularly sensitive to BPA at multiple points in the life span including embryonic development, the perinatal period, puberty and adulthood (Markey et al., [@B127], [@B126]; Wadia et al., [@B225]), effects which may be mediated by an ERα-dependent mechanism (Recchia et al., [@B166]; Vivacqua et al., [@B221]). Defects include intraductal hyperplasias, increased sensitivity to endogenous estradiol and the development of neoplastic lesions (Durando et al., [@B57]).

Like genistein, BPA may also compromise sexual differentiation in the brain. We determined that exposure to 500 μg BPA for only 2 days, beginning the day after birth, feminized the number of dopaminergic neurons in the pubertal male rat AVPV (Patisaul et al., [@B155]) but not the overall size of the AVPV (Patisaul et al., [@B156]). Another laboratory subsequently reported decreased numbers of dopaminergic neurons in the AVPV of female mice exposed from gestation through lactation to lower, environmentally relevant doses (Rubin et al., [@B172]). Collectively, these studies suggest that each sex may be susceptible to different doses, a hypothesis that is intriguing and merits further exploration as the observed discrepancy could also be due to differences in, route of administration, duration of exposure or species; all of which illustrates the challenge of translating animal data to human risk assessments. Notably, other studies have also reported phenotypic changes in the AVPV after neonatal exposure to EDCs (Gore, [@B72]). Exposure to Aroclor 1221, a mixture of PCBs, through late gestation and the early neonatal period reduced the number of ERβ-expressing cells in the adult female rat AVPV without markedly affecting volume (Salama et al., [@B176]). Similarly, exposure to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) on gestational day 15 abolished the sexually dimorphic expression of GAD 67 in the rat AVPV on PND 3 (Hays et al., [@B88]). Although these data support the hypothesis that sexual differentiation of the brain in general, and within the AVPV specifically, may be vulnerable to endocrine disruption, the physiological and functional consequences of these changes has yet to be convincingly established.

Considerable scientific debate remains about whether or not humans are exposed to truly significant levels of BPA. Human serum levels have generally been found to be in the range of 0.2--20 ng/ml (Vandenberg et al., [@B216]) and urinary levels increase following the consumption of beverages from polycarbonate bottles containing BPA (Carwile et al., in press). Most rodent studies evaluating potential adverse effects of BPA did not measure serum levels in exposed animals making it difficult to determine if the outcomes can be extrapolated to humans. Further complicating the issue is that humans and rodents metabolize BPA differently, however both species, along with non-human primates, exhibit comparable levels of the unconjugated (estrogenically active) form of BPA in fluids and thus perhaps equally susceptible to its effects (reviewed in detail by Vandenberg et al., [@B217]). Like DDT, the fate of BPA may ultimately be decided by politics and public perception, rather than a regulatory action based on a measured evaluation of the scientific evidence. As this manuscript went to press (May, 2009) Canada declared BPA a "toxin" and Minnesota became the first state to ban the use of BPA in baby bottles and cups. Many other states had similar laws pending. In October of 2008, the Food and Drug Administration reaffirmed its conclusion that BPA use in food containers does not pose a public health threat, a decision that was met with considerable criticism. Not long after, Nalgene and most baby bottle manufacturers announced that they would no longer use BPA in the manufacturing of their products and bottles labeled "BPA-Free" are becoming increasingly common in Wal-Mart and other retail outlets.

Endocrine Disruption of Male Reproductive Physiology by DDT and the Phthalates
==============================================================================

Endocrine disruption can also happen in males. One of the most notable wildlife cases has been documented by researchers at the University of Florida who discovered numerous genital malformations, poor hatching success, and a sex ratio heavily skewed towards females among alligators living in a polluted central Florida lake. This lake had become heavily contaminated with DDT, difocol, their metabolites, and other pesticides as the result of an industrial spill (Guillette et al., [@B84], [@B85]; Milnes et al., [@B136]; Semenza et al., [@B180]). In mammals and birds, gonadal differentiation (the development of either an ovary or testis) is determined by the sex chromosomes. In non-mammalian vertebrates, including reptiles, incubation temperature during a critical window midway through development, influences which gonad forms and thus the sex of the animal. Guillette and colleagues discovered that exposure to estrogens or estrogenic EDCs can override or interact with this effect of temperature resulting in intersex individuals, males with abnormally low plasma testosterone levels, genital abnormalities, and malformation of the gonads (in both sexes). Exposing turtle or alligator eggs experimentally with the DDT metabolite DDE or estradiol induced similar effects (Bergeron et al., [@B21]; Crews et al., [@B44]; Gale et al., [@B68]; Guillette et al., [@B82]) conclusively demonstrating that endocrine disruption of male sex determination and the differentiation of the male reproductive system is possible. Reproductive abnormalities within reptiles living on this lake persist, even more than three decades after the initial spill, demonstrating that defects can impact multiple generations, particularly when the compounds are strongly lipophilic and have long half-lives.

In humans, there is growing evidence for, but considerable debate over, whether human male reproductive health is truly declining, and whether EDCs play any role in the perceived decline. In 1992, Carlsen and colleagues conducted a comprehensive review of the literature on human semen quality. Their systematic analysis of 61 published papers, incorporating data collected from nearly 15,000 men, revealed a statistically significant decline in mean seminal volume and sperm concentration over the last 50 years (Carlsen et al., [@B35]). This finding was widely publicized in the media and subsequently replicated by other investigators, although there appear to be significant regional differences in the severity of the effect (Swan et al., [@B206], [@B205]). Similarly, the incidence of testicular cancer and congenital abnormalities such as hypospadias and cryptorchidism also appear to be increasing (Adami et al., [@B2]; SEER, [@B179]; Sharpe, [@B187]) signifying a comprehensive decline in male reproductive health over the past 50 years. Doubt over the conclusions from these analyses persist however, because reliance on historical data sets (retrospective studies) restricts the ability to control for differences in data collection methods. With this caveat in mind, one feature of the semen data that stands out is an apparent birth cohort effect, with younger generations having poorer semen quality than older generations (Irvine, [@B99]). This suggests that insult in fetal life could be responsible for the defects that emerge later. This hypothesis is supported by epidemiological data showing that the occurrence of one disorder, such as low sperm count, is a risk factor for the occurrence of another, such as testicular cancer. This relationship has led a Danish research group to propose that low sperm counts, hypospadias, cryptorchidism and testicular germ cell cancer are interrelated disorders, all of which have their roots in fetal development, comprising a "testicular dysgenesis syndrome" (TDS) (Boisen et al., [@B22]; Skakkebaek et al., [@B194], [@B193]). The TDS hypothesis proposes that these disorders are all manifestations of disturbed prenatal testicular development resulting from abnormal hormone synthesis or action during reproductive tract development.

Androgens, including testosterone, produced by the fetal testes are essential for the differentiation of the epididymis, vas deferens and the seminal vesicles from the Wolffian ducts. Differentiation of the prostate and external genitalia requires 5α-dihydrotestosterone (DHT), the most potent androgen produced by the testis catalyzed from testosterone by the enzyme 5α-reductase. Failure to produce DHT, or sufficient levels of DHT, can lead to poorly developed or malformed external genitalia. Therefore toxicants that interfere with 5α-reductase or the interaction of DHT with the androgen receptor during development can impair proper development of male genitalia and the prostate. For example, administration of the androgen receptor antagonist, flutamide during male reproductive tract development induces multiple abnormalities of the external genitalia including hypospadias and cryptorchidism in both rats and monkeys (Herman et al., [@B93]; Mylchreest et al., [@B138]). Environmental toxicants are also known to interfere with male genital development. One of the earliest animal studies designed to test the hypothesis that chemical agents could interfere with androgen action was conducted in 1950 using chickens. Injection of DDT resulted in markedly undersized testes and inhibited the development of the comb and wattle. It was later determined that DDT and its metabolites function as anti-androgens (as well as estrogen mimics) and compete with endogenous androgens for access to the androgen receptor.

One class of compounds that has recently received considerable attention for potentially contributing to TDS is the phthalates. There are many different kinds of phthalates and the two considered to have the greatest potential to impact male reproduction are dibutyl phthalate (DBP) and diethylhexyl phthalate (DEHP, Figure [1](#F1){ref-type="fig"}). DBP is used in many personal care products such as lotions, cosmetics, nail polish, and perfume. DEHP is primarily used as a plasticizer in the production of flexible products including vinyl, medical tubing and toys. Infants in neonatal intensive care units have some of the highest urinary phthalate levels observed to date, presumably a result of exposure through medical tubing and devices (Calafat et al., [@B31]; Weuve et al., [@B229]). A series of studies conducted in rats in the late 1990s was the first to demonstrate that phthalates could interfere with the ability of testosterone to masculinize the male reproductive tract. Exposure *in utero*, when the genitals are being formed, resulted in a number of genital malformations including hypospadias and hemorrhagic testes (Gray et al., [@B80]; Wolf et al., [@B235]). Thus it is plausible that neonatal exposure to phthalates could induce TDS. Interestingly, the phthalates do not produce their effects by antagonizing the androgen receptor, but rather by interfering with the production of androgens in the fetal testis (David, [@B48]). Exposure to phthalates during human pregnancy has now been associated with smaller (feminized) anogenital distance in infant boys (Swan et al., [@B207]). Epidemiological evidence has also positively correlated higher urinary phthalate levels with lower sperm counts and an increased likelihood of sperm with damaged DNA in adult men (Duty et al., [@B58]; Hauser, [@B86]; Pant et al., [@B150]; Wirth et al., [@B233]). Although it is important to keep in mind that correlation does not prove causation, these newly emerging epidemiology studies are the best evidence to data that phthalates have the potential to affect male reproductive health in humans.

Mixture Effects: When the Quality of Bird Song Constitutes "False Advertising"
==============================================================================

Intriguingly, exposure to EDCs can also enhance the masculinization of some traits but this many not translate to improved reproductive fitness. A good example of this occurred in song birds exposed to a mixture of compounds including phthalates. In song birds, song production is controlled by discrete neural pathways which develop and operate under the influence of steroid hormones. Estrogens, as well as androgens to some degree, are essential for proper sex specific organization of the song system. According to sexual selection theory, male secondary sex characteristics, including the production of elaborate songs, have evolved as indicators of male quality and in response to female preferences. Thus, modification of the song system by exposure to estrogenic contaminants could affect song quality and, as a result, how attractive exposed males are to potential mates. A recent experiment by Markman and colleagues tested this hypothesis using European starlings (*Sturnus vulgaris*) (Markman et al., [@B128]). The research group first observed the foraging habits of wild starlings at 20 sewage treatment sites and determined that earthworms were a primary prey species. Subsequent analysis of these earthworms revealed that they were heavily contaminated with 17β-estradiol (E2, from human wastewater), phthalates and BPA. A daily exposure for each compound was then estimated. Wild-caught juvenile birds were then maintained in the laboratory and exposed to either vehicle, 200 ng E2 or the environmentally relevant mixture (200 ng E2, 640 ng phthalates, 80 ng BPA) daily by injecting each preparation into a mealworm. The birds were exposed from October to April, when foraging on sewage beds is common, prior to the onset of the breeding season in the spring. Males exposed to the mixture had significantly enhanced song production including a more complex song repertoire, an increased number of song bouts, and longer songs. This was accompanied by enlargement of an important song nucleus, the HVC, in the males fed the mixture compared to control males. Females preferred the song of males fed the mixture to males fed either the vehicle or the E2 alone.

Enhanced song production, however, in this case appears to be a false indicator of male quality because subsequent analysis found that, even though circulating androgen levels were comparable to controls, the males fed the mixture were immunocompromised. Thus, although EDCs enhanced the masculinization of the song system, by misleading females into choosing less fit males the effect could subsequently decrease the overall fitness of the population.

Interestingly, males fed only E2 did not show enhanced song production or larger song nuclei demonstrating that this component of the mixture was insufficient on its own to influence this estrogen sensitive behavior. This finding emphasizes the concern that although some estrogenic compounds may not produce effects at low levels on their own, they may ultimately contribute to disruption when contained within a mixture of compounds with similar mechanisms of action. This concern is potentially considerable for a number of reasons. Perhaps one of the most worrisome is that, because most laboratory animal diets are derived from soy and therefore contain relatively high levels of genistein and other phytoestrogens (actual amounts vary from batch to batch) this background of EDC exposure could impact endocrine disruption research (Brown and Setchell, [@B27]; Degen et al., [@B50]). Could this be a significant potential confound? A research group at Washington State University recently reported that they could not replicate previously published BPA effects in the mouse ovary. They ultimately concluded that effects were only observed in mice maintained on soy-rich diets leading the authors to hypothesize that diet, along with methodological differences, could explain why the literature surrounding "low dose" effects of BPA is fragmented and inconsistent (Muhlhauser et al., [@B137]). The concept of mixture effects is an evolving area of endocrine disruption research, the results of which could have profound implications for other disciplines including neuroendocrinology and behavioral biology.

Transgenerational Effects and the Emerging Field of Epigenetics
===============================================================

It is now becoming evident that the effects of EDC exposure are not necessarily limited to the exposed individual. Many of these compounds are now recognized to have transgenerational effects and in some cases the effects within subsequent generations are more profound than those seen in the first generation (Jirtle and Skinner, [@B105]; Steinberg et al., [@B199]). For example, there is emerging concern that the children of DES daughters (referred to as DES granddaughters) might also experience reproductive problems. For these girls, their exposure occurred when they were germ cells in their mother\'s developing ovary, within the womb of their grandmother. If true, it would be the first instance in humans which conclusively demonstrates that persistent, generational effects can result from an *in utero* exposure to a potent estrogen (Newbold et al., [@B142]). This concern for DES granddaughters arose from data obtained in laboratory animal studies which indicated that the offspring of females exposed *in utero* were more likely to develop reproductive tract lesions than unexposed control animals (Newbold et al., [@B142], [@B143]). Other studies have produced evidence that DES effects across generations can be transmitted through the paternal line as well (Walker and Haven, [@B226]). So far, there is not enough human data to indicate a trend for deleterious effects in DES granddaughters, largely because this cohort is so young. Continued monitoring of these women as they age will ultimately be required to determine if there are transgenerational effects of prenatal DES exposure in humans.

The precise mechanisms through which endocrine disrupting effects transmit to subsequent generations are not well understood but emerging evidence indicates alteration of chromosomal structure or other epigenetic mechanisms might be the primary method. Epigenetic inheritance involves changes in gene expression patterns without changes in gene sequence. Such effects include DNA methylation and histone modifications, among others. In most cases, methylation of gene promoter regions abrogates gene transcription while acetylation of the histone tail enhances it (Dolinoy et al., [@B54]; Gore, [@B72]; Ho and Tang, [@B94]). These processes can be influenced by environmental factors and if these modifications occur within the germ cell lines then transmission to subsequent generations is possible (Giusti et al., [@B71]; Gore, [@B72]; Jirtle and Skinner, [@B105]). This newly discovered and evolving area of research has once again transformed the field of toxicology and introduced a novel method by which endocrine disruptors and other toxicants can affect vertebrate physiology and behavior.

A well characterized animal model demonstrating the potential for epigenetic modifications to impact future generations involves the manipulation of the murine agouti gene in a specialized mouse strain (Duhl et al., [@B56]; Vrieling et al., [@B224]). In this strain, the degree of methylation on an inserted transposable element can vary dramatically and correlates with a wide distribution in coat color that ranges from yellow (unmethylated) to brown (methylated) as well as the occurrence of diabetes, obesity and tumorigenesis. Maternal dietary supplementation of methyl-donors (folic acid, vitamin B~12~, choline and betaine) during pregnancy can shift the coat color of offspring towards the brown pseudoagouti phenotype (Duhl et al., [@B56]; Waterland and Jirtle, [@B227]; Wolff et al., [@B236]) demonstrating the effect maternal diet can have on offspring adult phenotypes. Even more intriguing is the observation that maternal exposure to genistein induces hypermethylation, again shifting the coat color of the offspring to brown (Dolinoy et al., [@B55]), but unlike other methyl donors, genistein protected these offspring from the obesity normally associated with the darker color. These results illustrate the potential for genistein and perhaps other EDCs to epigenetically alter the phenotype of subsequent generations through *in utero* exposure. Other compounds, including polychlorinated biphenyls (PCBs) (Aubrecht et al., [@B10]; Schiestl et al., [@B177]) and the fungicide vinclozolin (Anway et al., [@B9]; Gore, [@B72]) have also been shown to produce transgenerational effects, perhaps through epigenetic mechanisms.

When a pregnant animal is exposed to an EDC, it is important to keep in mind that the mother (F~0~), the embryo (F~1~) and the F~2~ generation (as germ cells) are all directly exposed. While the majority of studies concerning transgenerational epigenetic effects of EDCs have not been carried past the F~2~ generation it is important to note that, to rule out direct exposure effects, the F~3~ generation should also be examined for abnormalities. It is also critical to appreciate that epigenetic effects can also occur outside of the germ line. Thus these mechanisms may underlie many observed EDC effects and could explain how compounds which are only weakly estrogenic, like BPA, can produce appreciable, lasting results at such low levels (Jirtle and Skinner, [@B105]). The ability of most estrogenic EDCs, such as DES, genistein and BPA, to pass from mother to offspring through placental blood flow or lactational transfer makes the possibility for epigenetic, transgenerational effects likely (Crews and McLachlan, [@B45]; Franke and Custer, [@B65]; Mably et al., [@B124]; Newbold, [@B140]; Ruden et al., [@B174]; Sun et al., [@B202]; Wisniewski et al., [@B234]). Although the specific mechanisms underlying the observed transgenerational effects of DES in animals have proven difficult to elucidate, emerging research implicates epigenetic modifications as a significant component (Gore, [@B72]; Li et al., [@B120]; Newbold, [@B140]). Newbold and colleagues have recently shown that alterations in gene methylation patterns of estrogen-responsive genes following DES exposure can be passed on to the next generation (Li et al., [@B121], [@B120]; Newbold, [@B140]). Studies exploring how epigenetics might explain the "fetal origins of adult disease" are currently underway in DES granddaughters, but results will emerge slowly because of the relatively young age of the subjects. Although clear indicators of illness occurred early in some individuals, most carcinogenic and reproductive tract abnormalities in DES daughters did not occur until at least middle age and it will be another decade before most of the DES granddaughters reach that age as well. Thus, many transgenerational effects in these individuals have likely not yet emerged (Giusti et al., [@B71]; Rubin, [@B173]).

Conclusions
===========

While it appears clear, in both animals and humans, that exposure to EDCs can have adverse effects on reproductive physiology and behavior, controversies surrounding this topic remain. Importantly, recognition of the prevalence of these compounds in the environment and their potential to adversely affect both wildlife and human populations is increasing among scientists, policy makers, and the general public. Further efforts to understand the mechanisms underlying EDC effects, particularly those seen at environmentally relevant doses by compounds with low hormonal potency, are necessary to adequately develop a public health strategy for preventing or combating their effects. The ability of these compounds to permanently affect the epigenome could be potentially catastrophic to the welfare of future generations and requires further attention by both toxicologists and endocrinologists. While research surrounding this topic is not conclusive, particularly in humans, there is certainly sufficient evidence to warrant concern about potential long term effects in both wildlife and humans. Obtaining absolute proof of endocrine disruption by BPA, phthalates, and other compounds with weak hormonal activity in humans is likely impossible because it would obviously be unethical to conduct a double-blind study where one group is exposed to a suspected toxicant. Research in animals, however, is robust and indicates that disruption of sex specific behavior, neuroendocrine circuitry and physiology is possible and, in some cases, transgenerational.

Unfortunately, it is extraordinarily difficult for individuals to make informed choices about how to reduce their potential exposure because chemicals in the US are not routinely screened or tested for endocrine disrupting properties. The Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) was formed by Congress in 1996 to make specific recommendations to the EPA about how to test and screen compounds for endocrine disrupting properties, but progress has been frustratingly slow. A list of compounds to be screened was not compiled until April of 2009 and only 67 chemicals were included, a tiny fraction of the thousands of compounds now suspected of having endocrine disrupting properties. Moreover, it is often impossible to determine which plastics, cosmetics, toys, or other household items contain any of these compounds so consumers have no adequate way to avoid them if desired. The thought that the mixture of chemicals a pregnant woman is exposed to during her pregnancy could affect not only her daughter\'s fecundity but also her granddaughter\'s is alarming and a major reason why the topic of endocrine disruption continues to receive global attention by scientists and the general public.
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